Adventures in Drug Discovery: Potent Agents Based on Ligands for Cell-Surface Receptors
- 6 September 2006
- journal article
- research article
- Published by American Chemical Society (ACS) in Accounts of Chemical Research
- Vol. 39 (11) , 831-840
Abstract
How does one go about discovering new drugs? This question is addressed by descriptions of drug discovery research in three project areas that pertain to antagonist ligands for cell-surface receptors. The molecular targets of interest are protease-activated receptor-1 (PAR-1), vasopressin receptors (V1a and V2 subtypes), and the fibrinogen receptor (GPIIb/IIIa). I present different approaches to the identification of high-affinity ligands for these receptors, en route to drug candidates. The PAR-1 project resulted in a pharmacological tool compound that facilitated in vivo proof-of-principle studies, whereas the vasopressin and fibrinogen receptor projects resulted in several preclinical development compounds, three of which advanced into human clinical trials.Keywords
This publication has 35 references indexed in Scilit:
- CHARACTERIZATION OF RWJ‐351647, A NOVEL NONPEPTIDE VASOPRESSIN V2RECEPTOR ANTAGONISTClinical and Experimental Pharmacology and Physiology, 2006
- Blockade of the Thrombin Receptor Protease-Activated Receptor-1 with a Small-Molecule Antagonist Prevents Thrombus Formation and Vascular Occlusion in Nonhuman PrimatesThe Journal of Pharmacology and Experimental Therapeutics, 2003
- Seven-transmembrane receptorsNature Reviews Molecular Cell Biology, 2002
- Molecular pharmacology of AVP and OT receptors and therapeutic potentialDrug News & Perspectives, 1999
- Pharmacological characterization of the human vasopressin receptor subtypes stably expressed in Chinese hamster ovary cellsBritish Journal of Pharmacology, 1998
- Integrin affinity modulationTrends in Cell Biology, 1998
- Protease-activated receptor 3 is a second thrombin receptor in humansNature, 1997
- Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settingsAdvanced Drug Delivery Reviews, 1997
- Solid-phase parallel synthesis applied to lead optimization: Discovery of potent analogues of the GPIIb/IIIa antagonist RWJ-50042Bioorganic & Medicinal Chemistry Letters, 1996
- Integrins: Versatility, modulation, and signaling in cell adhesionCell, 1992